Home Cart Sign in  
Chemical Structure| 1169562-71-3 Chemical Structure| 1169562-71-3

Structure of XL413 HCl
CAS No.: 1169562-71-3

Chemical Structure| 1169562-71-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XL413 HCl is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, > 60-fold selectivity against CK2, > 10-fold selectivity against PIM, and > 300-fold selectivity against a panel of over 100 protein kinases.

Synonyms: BMS-863233; XL413; BMS-863233 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of XL413 HCl

CAS No. :1169562-71-3
Formula : C14H13Cl2N3O2
M.W : 326.18
SMILES Code : O=C1C(OC2=CC=C(Cl)C=C23)=C3N=C([C@H]4NCCC4)N1.[H]Cl
Synonyms :
BMS-863233; XL413; BMS-863233 hydrochloride
MDL No. :MFCD28023577

Safety of XL413 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of XL413 HCl

Hedgehog

Isoform Comparison

Biological Activity

Description
XL413 (BMS-863233) hydrochloride is an orally active and selective CDC7 inhibitor (IC50=3.4 nM). XL413 hydrochloride exhibits favorable pharmacokinetic profiles and effectively suppresses tumor growth in rodent models. XL413 hydrochloride serves as a valuable tool in cancer research [1].
Target
  • Cdc

    Cdc7, IC50:3.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SKOV-3 cells 10.0 µM 36 hours Evaluate the cell viability inhibition rate of sequential treatment with XL413 and carboplatin, results showed that sequential treatment with CBP followed by XL413 significantly increased the inhibition rate PMC10687335
OVCAR-3 cells 10.0 µM 36 hours Evaluate the cell viability inhibition rate of sequential treatment with XL413 and carboplatin, results showed that sequential treatment with CBP followed by XL413 significantly increased the inhibition rate PMC10687335
H69-AR cells 50 μM 48 hours To evaluate the synergistic effect of XL413 with chemotherapy, the results showed that the combination of XL413 and chemotherapy significantly inhibited cell growth. PMC9892530
H446-DDP cells 80 μM 48 hours To evaluate the synergistic effect of XL413 with chemotherapy, the results showed that the combination of XL413 and chemotherapy significantly inhibited cell growth. PMC9892530
Xenopus egg extracts 100 μM 40 minutes Evaluate the effect of XL413 on the phosphorylation of Mcm4 and Mcm2, showing that XL413 only delayed the hyper-phosphorylation of Mcm4 but efficiently inhibited the phosphorylation of Mcm2 at S40 and S53. PMC5357733
HeLa cells 10 μM 2 hours Test the effect of XL413 on the phosphorylation of Mcm4 in HeLa cells, showing that XL413 suppressed the phosphorylation of chromatin-bound Mcm4 as well as Mcm2 at S40 and S53. PMC5357733
K562 cells 33 μM 24 hours Increase the efficiency of homology-directed repair (HDR), HDR increased by 1.8-fold PMC7193628
K562 cells 10 μM 24 hours Optimize CDC7 inhibition, explore the impact of different exposure timing on HDR PMC7193628
A375 cells 1 µM 24 hours XL413 treatment inhibited the short-term survival and long-term growth of A375 cells and significantly inhibited cell growth in soft agar. PMC9356103
M14 cells 1 µM 24 hours XL413 treatment inhibited the short-term survival and long-term growth of M14 cells and significantly inhibited cell growth in soft agar. PMC9356103
SKMEL-239 cells 1 µM 24 hours XL413 treatment inhibited the short-term survival and long-term growth of SKMEL-239 cells and significantly inhibited cell growth in soft agar. PMC9356103

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice OVCAR8 tumor xenograft and PDX mouse models, HGS1 mouse model Intraperitoneal injection 40 mg/kg every 2 days Enhancement of anti-tumor immunity and improved therapeutic outcomes. PMC11615783
C57BL/6 mice orthotopic xenograft model Oral 50 mg/kg 6 days per week limited tumor growth and prolonged mouse survival. PMC10367558
BALB/c Nude mice subcutaneous and intraperitoneal tumor models Oral gavage 50 mg/kg 5 days per week for 3 weeks Evaluate the in vivo efficacy of sequential treatment with carboplatin and XL413 against ovarian cancer, results showed that sequential treatment significantly inhibited tumor growth and prolonged survival PMC10687335
Nude mice H69-AR xenograft model intraperitoneally 20 mg/kg administered on day 1, 3, and 5 of each cycle for 3 cycles, each cycle lasting 7 days To evaluate the synergistic effect of XL413 with chemotherapy, the results showed that the combined treatment significantly inhibited tumor growth. PMC9892530
Nude mice Athymic nude mice Intraperitoneal injection 50 mg/kg Every other day until the end of the experimental period XL413 treatment inhibited melanoma tumor growth and metastasis in mice. PMC9356103

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.07mL

0.61mL

0.31mL

15.33mL

3.07mL

1.53mL

30.66mL

6.13mL

3.07mL

References

 

Historical Records

Categories